Company intelligence / Profile preview

JPR Royalty Sub

Delaware, United States

Ownership: Private
Development stage: Other

Overview

JPR Royalty Sub is a wholly-owned subsidiary of BioCryst Pharmaceuticals, established to hold rights to royalties and milestone payments from sales of the antiviral RAPIACTA (peramivir) in Japan and related milestone payments under a licensing agreement with Shionogi. The company itself does not conduct R&D or clinical operations.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Investors

Partnerships

Shionogi

Beyond the preview

Go deeper on JPR Royalty Sub.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JPR Royalty Sub.

Explore the full profile